ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

LAD191

A development code.

Its studies are mostly in Hidradenitis Suppurativa · Autoimmune Diseases, led by Almirall.

Furthest: phase 2, since Sep 2, 20252 company-led studies, 1 open or runningNext primary completion: May 25, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Almirall21 open or runningphase 2since Sep 2, 2025Jun 28, 2024May 25, 2027phase 2 · NCT07151937

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 28, 2024First study: phase 1 study in Autoimmune DiseasesFirst studyNCT06488209 · 69 enrolled · United States
  2. Sep 2, 2025Phase 2 study in Hidradenitis SuppurativaNCT07151937 · 200 planned · Spain

Ahead

  1. May 25, 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07151937

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07151937Hidradenitis Suppurativa · Spain2RecruitingMay 25, 2027200
NCT06488209Autoimmune Diseases · United States1CompletedApr 3, 202569

How it is read

Names in the registry

  • “LAD191”, 2 entries

Codes read as this program: LAD191.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.